Nachrichten zu Atea Pharmaceuticals

Startseite > Aktien > Atea Pharmaceuticals > Nachrichten

Atea Pharmaceuticals Aktie

Aktie

ISIN: US04683R1068 WKN: A2QGE7 SYM: AVIR Land Flagge US

USA

Zur Watchlist hinzufügen Zum Portfolio hinzufügen

Zum Portfolio hinzufügen

3,8900

USD

+0,52 %

+0,0200 USD

Letzter Kurs 02:00:00 Nasdaq

Geldkurs

16.09.24

3,8800

USD

2.200 STK

Briefkurs

16.09.24

3,8900

USD

1.400 STK

Atea Pharmaceuticals Aktie kaufen

Kauf

Verkauf

Neueste Nachrichten

Atea Pharmaceuticals Provides Update on Global Phase 3 SUNRISE-3 Trial Evaluating Bemnifosbuvir for Treatment of COVID-19 13.09.24 · globenewswire · Atea Pharmaceuticals
Atea Pharmaceuticals Announces Publication of Additional Data Further Highlighting Bemnifosbuvir’s Metabolic Activation Pathway 28.08.24 · globenewswire · Atea Pharmaceuticals
Atea Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update 07.08.24 · globenewswire · Atea Pharmaceuticals
Atea Pharmaceuticals to Host Second Quarter 2024 Financial Results Conference Call on August 7, 2024 31.07.24 · globenewswire · Atea Pharmaceuticals
Atea Pharmaceuticals Presents Positive Initial Phase 2 Data for Bemnifosbuvir and Ruzasvir Combination for Treatment of Hepatitis C Virus at EASL Congress 2024 05.06.24 · globenewswire · Atea Pharmaceuticals
Atea Pharmaceuticals to Present at the Jefferies Healthcare Conference 29.05.24 · globenewswire · Atea Pharmaceuticals
Atea Pharmaceuticals Presents New Data Showcasing Potential Best-in-Class Combination Profile of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus at EASL Congress 2024 22.05.24 · globenewswire · Atea Pharmaceuticals
Atea Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update 14.05.24 · globenewswire · Atea Pharmaceuticals
Atea Pharmaceuticals to Host First Quarter 2024 Financial Results Conference Call on May 14, 2024 07.05.24 · globenewswire · Atea Pharmaceuticals
Atea Announces Presentation of Data Highlighting Favorable Safety Profile of Bemnifosbuvir at ESCMID Global 2024 29.04.24 · globenewswire · Atea Pharmaceuticals
Atea Pharmaceuticals Completes Patient Enrollment in Global Phase 3 SUNRISE-3 Trial Evaluating Oral Antiviral Bemnifosbuvir for COVID-19 in High-Risk Patients 27.03.24 · globenewswire · Atea Pharmaceuticals
Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update 28.02.24 · globenewswire · Atea Pharmaceuticals

1
2

Atea Pharmaceuticals Provides Update on Global Phase 3 SUNRISE-3 Trial Evaluating Bemnifosbuvir for ... 196 Leser

Atea Pharmaceuticals Announces Publication of Additional Data Further Highlighting ... 216 Leser
Atea Pharmaceuticals Provides Update on Global Phase 3 SUNRISE-3 Trial Evaluating Bemnifosbuvir for ... 196 Leser

Atea Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update 332 Leser
Atea Pharmaceuticals to Host First Quarter 2024 Financial Results Conference Call on May 14, 2024 300 Leser
Atea Pharmaceuticals Announces Positive Initial Data from Phase 2 Study for Hepatitis C Virus (HCV) ... 220 Leser
Atea Pharmaceuticals Announces Publication of Additional Data Further Highlighting ... 216 Leser
Atea Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference 216 Leser
Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides ... 216 Leser
Atea Announces Presentation of Data Highlighting Favorable Safety Profile of Bemnifosbuvir at ... 204 Leser
Atea Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update 200 Leser
Atea Pharmaceuticals Provides Update on Global Phase 3 SUNRISE-3 Trial Evaluating Bemnifosbuvir for ... 196 Leser
Atea Pharmaceuticals to Host Fourth Quarter and Full Year 2023 Financial Results Conference Call on ... 164 Leser